Lupin receives highest ESG rating from CDP for climate change and water security
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The partnership initially will focus on cardiovascular and kidney diseases
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated